Analysts Set Teladoc Health, Inc. (NYSE:TDOC) Price Target at $9.60

Shares of Teladoc Health, Inc. (NYSE:TDOC) have earned an average recommendation of “Hold” from the eighteen analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, twelve have issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $9.60.

Several equities research analysts recently commented on TDOC shares. Evercore ISI cut their target price on Teladoc Health from $9.00 to $8.00 and set an “in-line” rating on the stock in a research report on Thursday, October 30th. Zacks Research downgraded shares of Teladoc Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Bank of America lowered their price objective on shares of Teladoc Health from $9.00 to $8.00 and set a “neutral” rating for the company in a research note on Tuesday, November 25th. Barclays assumed coverage on shares of Teladoc Health in a research note on Tuesday, December 9th. They set an “equal weight” rating and a $8.50 target price on the stock. Finally, Citigroup raised their price target on shares of Teladoc Health from $9.50 to $10.50 and gave the stock a “neutral” rating in a report on Tuesday, October 21st.

Teladoc Health Stock Up 0.5%

Shares of NYSE TDOC opened at $7.27 on Thursday. The company’s 50 day moving average price is $7.79 and its 200-day moving average price is $7.81. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.60 and a current ratio of 2.70. Teladoc Health has a 52-week low of $6.35 and a 52-week high of $15.21. The company has a market capitalization of $1.29 billion, a P/E ratio of -5.68 and a beta of 2.04.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, October 29th. The health services provider reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.05. The business had revenue of $626.44 million during the quarter, compared to the consensus estimate of $625.66 million. Teladoc Health had a negative net margin of 8.84% and a negative return on equity of 10.59%. Teladoc Health’s quarterly revenue was down 2.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.19) earnings per share. Teladoc Health has set its Q4 2025 guidance at -0.250–0.100 EPS. Equities analysts forecast that Teladoc Health will post -1.16 earnings per share for the current year.

Insider Transactions at Teladoc Health

In related news, CEO Charles Divita III sold 17,138 shares of the stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $7.63, for a total value of $130,762.94. Following the transaction, the chief executive officer directly owned 201,036 shares in the company, valued at $1,533,904.68. This trade represents a 7.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Fernando M. Rodrigues sold 4,209 shares of Teladoc Health stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $7.48, for a total transaction of $31,483.32. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 33,288 shares of company stock valued at $251,684 in the last 90 days. Corporate insiders own 0.58% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TDOC. Vanguard Group Inc. raised its holdings in shares of Teladoc Health by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock worth $169,372,000 after acquiring an additional 891,732 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Teladoc Health by 23.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock worth $53,260,000 after purchasing an additional 1,325,106 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Teladoc Health by 2.1% in the second quarter. Geode Capital Management LLC now owns 4,150,197 shares of the health services provider’s stock worth $36,153,000 after purchasing an additional 84,356 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Teladoc Health by 5.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,571,673 shares of the health services provider’s stock valued at $20,471,000 after purchasing an additional 127,960 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its position in shares of Teladoc Health by 11.1% during the third quarter. Ameriprise Financial Inc. now owns 2,284,697 shares of the health services provider’s stock valued at $17,661,000 after buying an additional 227,385 shares during the last quarter. 76.82% of the stock is currently owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.